L3VLUP
ProSign in

RPRX in the 13F filings

Royalty Pharma PLC · CUSIP G7709Q104

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Q3 2026: 5 of 95 managers have filed so far; the filing deadline is 16 November 2026. Its figures cover those filers only, so it is not yet a picture of the tracked managers.

Quarter end
30 Sep 2026
the date the book describes
Filed
9 Nov 2026
latest of these filings; the earliest 9 Nov 2026
Managers listing it
3
at least, of 95 tracked, among listed positions
Comparable managers
5
filed both Q2 2026 and Q3 2026; 1 listed it in both
Shares listed
9,646,309
combined, among listed positions
Reported value
$563m
combined, at the quarter end

Among the 5 comparable managers: 1 buyer (opened or added shares) and 2 sellers (trimmed or exited), at least, among listed positions. Their net change in shares was -740,311.

Managers listing RPRX in Q3 2026

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2026, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

3 of 3 holders

ActionFiling
Baillie Gifford & Co9,151,948$534m0.50%Trimmed-863,6309 Nov 2026 (the filing on sec.gov)
Squarepoint Ops LLC486,393$28munder 0.1%Added+159,7529 Nov 2026 (the filing on sec.gov)
Acadian Asset Management LLC7,968$464kunder 0.1%Trimmed-36,4339 Nov 2026 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2026 to Q3 2026, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
10 in Q4 2024 to 1 in Q3 2026

Tracked managers listing it, at least.

05101520202120222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
RPRX by quarter
QuarterHoldersReported valueBuyersSellers
Q2 202010$1.8bnn.a.n.a.
Q3 20207$1.6bnn.a.n.a.
Q4 20205$1.9bnn.a.n.a.
Q1 20215$1.5bnn.a.n.a.
Q2 20218$1.5bnn.a.n.a.
Q3 20216$1.4bnn.a.n.a.
Q4 20218$1.8bnn.a.n.a.
Q1 20228$1.8bnn.a.n.a.
Q2 202210$3.2bnn.a.n.a.
Q3 202211$3.4bnn.a.n.a.
Q4 202217$3.4bnn.a.n.a.
Q1 202314$2.9bnn.a.n.a.
Q2 202316$2.3bnn.a.n.a.
Q3 202314$1.9bnn.a.n.a.
Q4 202313$2.1bn86
Q1 202410$2.2bn56
Q2 202412$1.7bn75
Q3 202410$2.0bn74
Q4 202410$1.6bn73
Q1 20259$2.3bn45
Q2 20259$2.4bn45
Q3 202511$1.9bn75
Q4 202510$2.4bn1714
Q1 202615$3.1bn1816
Q2 202615$3.9bn2117
Q3 20261$534m12

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

RPRX and LLY →RPRX and JNJ →RPRX and VRTX →Choose a stock to compare with RPRX →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own RPRX, latest filings →Back to the 13F Explorer →